Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 28, 2018 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene. QR-313 is a...
June 12, 2018 07:00 ET | Source: ProQR Therapeutics N.V.

ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start in the second quarter of 2018 LEIDEN, the Netherlands, June 12, 2018 (GLOBE NEWSWIRE) --...